DOI:
10.1055/s-00000011
DMW - Deutsche Medizinische Wochenschrift
LinksClose Window
References
Van Geel R, Elez E, Bendell JC. et al.
Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer.
J Clin Oncol 2014;
32: 5s
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.